Dysregulated B cell activation is a key driver in the pathogenesis of lupus, but monoclonal depleting antibodies, such as rituximab targeting the B cell antigen CD20, have failed to achieve primary efficacy endpoints in RCT (21, 25). Here, PPIB is linked to systemic lupus erythematosus.